

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage of Teva-Buprenorphine/Naloxone 8 mg/2 mg Sublingual Tablet (DIN 02424878) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 22, 2016**.

BUPRENORPHINE HCL/ NALOXONE HYDROCHLORIDE DIHYDRATE

8 MG / 2 MG SUBLINGUAL TABLET

00002408104	MYLAN-BUPRENORPHINE NALOXONE	MYP	\$ 2.3650
00002424878	TEVA-BUPRENORPHINE/NALOXONE	TEV	\$ 2.3650
00002295709	SUBOXONE	IUK	\$ 4.7300

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage of Taro-Carbamazepine 20 mg/ml Oral Suspension (DIN 02367394) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 22, 2016**.

CARBAMAZEPINE

20 MG / ML ORAL SUSPENSION

00002367394	TARO-CARBAMAZEPINE	TAR	\$ 0.0587
00002194333	TEGRETOL	NOV	\$ 0.0781

... continued from previous page

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Stieva-A Forte 0.1% Topical Cream (DIN 00662348) manufactured by GlaxoSmithKline, Retin-A Micro 0.1% Gel (DIN 02243914) manufactured by Valeant Canada Limitee/Limited will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of January 15, 2016, all claims for Retin-A Micro 0.1% Gel (DIN 02243914) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)
FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.579 2016/01